Diana Barb

Diana Barb, MD

Clinical Associate Professor

Department: MD-ENDOCRINOLOGY
Business Phone: (352) 273-8655
Business Email: dbarb@ufl.edu

About Diana Barb

Dr. Diana Barb received her medical degree from the University of Medicine and Pharmacy in Targu Mures Romania. She did a two year research fellowship, focusing on obesity, adiponectin and cancer at Beth Israel Deaconess Medical Center, Harvard Medical School in Boston, Massachusetts, followed by an Internship, Internal Medicine Residency and Endocrinology Fellowship at Emory University in Atlanta, Georgia. Subsequently, she joined the University of Florida as a Clinical Associate Professor in the Division of Endocrinology, DiabetesĀ & Metabolism.

Board Certifications

  • Endocrinology Diabetes & Metabolism
    American Board of Internal Medicine
  • Internal Medicine
    American Board of Internal Medicine

Clinical Profile

Subspecialties
  • Endocrinology, Diabetes and Metabolism
Areas of Interest
  • Diabetes
  • Obesity
  • Thyroid diseases

Publications

2022
Development and pilot testing of a conversation aid to support the evaluation of patients with thyroid nodules.
Clinical endocrinology. 96(4):627-636 [DOI] 10.1111/cen.14599. [PMID] 34590734.
2022
Prevalence and Characteristics of Hyperthyroidism Among US Sarcoidosis Patients.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. [DOI] 10.1016/j.eprac.2022.03.017. [PMID] 35378305.
2022
Response to: “Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored?”
Obesity (Silver Spring, Md.). 30(5):971-972 [DOI] 10.1002/oby.23422. [PMID] 35394120.
2021
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.
Diabetes care. 44(2):399-406 [DOI] 10.2337/dc20-1997. [PMID] 33355256.
2021
Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes.
The Journal of clinical endocrinology and metabolism. 106(11):e4360-e4371 [DOI] 10.1210/clinem/dgab417. [PMID] 34190318.
2021
PPAR-Ī³-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH.
Liver international : official journal of the International Association for the Study of the Liver. 41(11):2659-2670 [DOI] 10.1111/liv.15005. [PMID] 34219361.
2021
Prevalence and characteristics of self-reported hypothyroidism and its association with nonorgan-specific manifestations in US sarcoidosis patients: a nationwide registry study.
ERJ open research. 7(1) [DOI] 10.1183/23120541.00754-2020. [PMID] 33816601.
2021
Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.
PloS one. 16(6) [DOI] 10.1371/journal.pone.0251449. [PMID] 34077443.
2021
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease.
Obesity (Silver Spring, Md.). 29(11):1950-1960 [DOI] 10.1002/oby.23263. [PMID] 34553836.
2020
Adult hypophosphatasia manifests in a marathon runner.
BMJ case reports. 13(9) [DOI] 10.1136/bcr-2020-234764. [PMID] 32912883.
2020
Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
Journal of hepatology. 72(3):401-410 [DOI] 10.1016/j.jhep.2019.09.018. [PMID] 31589891.
2019
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes.
Diabetes, obesity & metabolism. 21(4):812-821 [DOI] 10.1111/dom.13584. [PMID] 30447037.
2019
Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial.
Journal of diabetes. 11(3):223-231 [DOI] 10.1111/1753-0407.12833. [PMID] 30073778.
2019
Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.
The Journal of clinical endocrinology and metabolism. 104(8):3327-3336 [DOI] 10.1210/jc.2018-02414. [PMID] 30848827.
2019
Profound Hypoglycemia in a Hospitalized Patient: Paraneoplastic Insulin-Like Growth Factor.
The American journal of medicine. 132(12):1414-1416 [DOI] 10.1016/j.amjmed.2019.05.045. [PMID] 31242436.
2019
Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes.
Diabetes care. 42(7):1348-1351 [DOI] 10.2337/dc18-2578. [PMID] 31221701.
2018
Inpatient Glucose Values: Determining the Nondiabetic Range and Use in Identifying Patients at High Risk for Diabetes.
The American journal of medicine. 131(4):443.e11-443.e24 [DOI] 10.1016/j.amjmed.2017.09.021. [PMID] 28993187.
2017
Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.). 65(4):1132-1144 [DOI] 10.1002/hep.28985. [PMID] 27981615.
2017
Reply to “statins and non-alcoholic steatohepatitis”.
Metabolism: clinical and experimental. 66:e3-e5 [DOI] 10.1016/j.metabol.2016.10.004. [PMID] 27865560.
2016
Pharmacological management of nonalcoholic fatty liver disease.
Metabolism: clinical and experimental. 65(8):1183-95 [DOI] 10.1016/j.metabol.2016.04.004. [PMID] 27301803.
2015
Increased cardiovascular disease, resource use, and costs before the clinical diagnosis of diabetes in veterans in the southeastern U.S.
Journal of general internal medicine. 30(6):749-57 [DOI] 10.1007/s11606-014-3075-7. [PMID] 25608739.
2015
Successful aging: Advancing the science of physical independence in older adults.
Ageing research reviews. 24(Pt B):304-27 [DOI] 10.1016/j.arr.2015.09.005. [PMID] 26462882.
2015
Translating What Works: A New Approach to Improve Diabetes Management.
Journal of diabetes science and technology. 9(4):857-64 [DOI] 10.1177/1932296815576000. [PMID] 25759182.
2014
Aging is associated with increased HbA1c levels, independently of glucose levels and insulin resistance, and also with decreased HbA1c diagnostic specificity.
Diabetic medicine : a journal of the British Diabetic Association. 31(8):927-35 [DOI] 10.1111/dme.12459. [PMID] 24698119.
2008
A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.
BJU international. 101(9):1084-9 [DOI] 10.1111/j.1464-410X.2008.07509.x. [PMID] 18399827.
2007
Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence.
The American journal of clinical nutrition. 86(3):s858-66 [DOI] 10.1093/ajcn/86.3.858S. [PMID] 18265479.
2007
Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway.
Endocrine-related cancer. 14(4):995-1005 [PMID] 18045951.
2006
Adiponectin: a link between obesity and cancer.
Expert opinion on investigational drugs. 15(8):917-31 [PMID] 16859394.
2006
Leptin, adiponectin and ghrelin: their role in energy and glucose homeostatis
. 52(4):190-197
2005
Circulating resistin levels are not associated with fat redistribution, insulin resistance, or metabolic profile in patients with the highly active antiretroviral therapy-induced metabolic syndrome.
The Journal of clinical endocrinology and metabolism. 90(9):5324-8 [PMID] 15956078.

Education

Fellowship – Endocrinology, Diabetes and Metabolism
2013 · Emory University
Residency – Internal Medicine
2011 · Emory University
Medical Degree
1999 · University of Medicine and Pharmacy of Targu Mures

Contact Details

Phones:
Business:
(352) 273-8655
Emails:
Business:
dbarb@ufl.edu
Addresses:
Business Mailing:
PO Box 100226
GAINESVILLE FL 32610
Business Street:
2004 MOWRY ROAD
2004 MOWRY RD
UF CLINICAL TRANSLATIONAL RESEARCH
GAINESVILLE FL 326103010